City Therapeutics Appoints Andy Orth as Chief Executive Officer

Orth brings more than 25 years of global industry experience to CEO role, with strong track record in corporate and commercial strategy City co-founder Dr. John Maraganore to retain active executive chair role to ensure company leads next-generation RNAi therapeutics CAMBRIDGE, Mass – City Therapeutics, Inc., a biopharmaceutical company leading the future of RNA interference (RNAi)-based medicine, today announced the appointment of Andrew “Andy” Orth … Continue reading City Therapeutics Appoints Andy Orth as Chief Executive Officer

Impact Newswire08/01/202508/01/2025

Europe

SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

Press Release – 11/21/2024 Leading community-based practice to utilize increased set of solid tumor applications Boston, MA and Rolle, Switzerland, November 21, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has … Continue reading SOPHiA GENETICS Announces Expanded Partnership with Tennessee Oncology

Impact Newswire22/11/202422/11/2024